当前位置: X-MOL 学术Int. J. Diabetes Dev. Ctries. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Liraglutide may affect visceral fat accumulation in diabetic rats via changes in FTO, AMPK, and AKT expression
International Journal of Diabetes in Developing Countries ( IF 0.7 ) Pub Date : 2021-09-14 , DOI: 10.1007/s13410-021-00974-0
Shan Xiao 1 , Jun Zhu 1 , Ye Yang 2 , Yuetong Liu 3
Affiliation  

Purpose

The aim of this study is to explore the effects of liraglutide (LRG) on the expression of FTO, AMPK, and AKT in the visceral adipose tissues of obese and diabetic rats and the underlying mechanisms thereof.

Methods

Thirty SPF-grade, male SD rats were randomly divided into the healthy control, diabetic model (DM), and DM + LRG groups. The DM and DM + LRG groups were administered normal saline and LRG (0.6 mg/kg/d), respectively. After 12 weeks, the body weight of the rats was measured, and their visceral adipose tissues were collected and weighed; the levels of serum biochemical indicators and FTO, AMPK, and AKT in these tissues were then measured using qRT-PCR and western blotting.

Results

Compared to the control group, the body weight and visceral fat accumulation and blood glucose, TG, TC, and LDL-C levels increased significantly, while the HDL-C levels decreased significantly, in the DM group (p < 0.05). After LRG treatment, the HDL-C levels increased significantly, but the levels of the other indicators decreased significantly (p < 0.05). Compared to the control group, the visceral adipose tissue levels of FTO and AKT increased significantly, while the AMPK levels decreased significantly in the DM group (p < 0.05). After LRG treatment, the FTO and AKT levels decreased significantly, and the AMPK levels increased significantly (p < 0.05).

Conclusion

LRG may activate and inhibit the AMPK and AKT pathways, respectively, and decrease FTO expression, thereby alleviating abdominal obesity in type 2 diabetes.



中文翻译:

利拉鲁肽可能通过 FTO、AMPK 和 AKT 表达的变化影响糖尿病大鼠内脏脂肪的积累

目的

本研究的目的是探讨利拉鲁肽(LRG)对肥胖和糖尿病大鼠内脏脂肪组织中 FTO、AMPK 和 AKT 表达的影响及其潜在机制。

方法

将 30 只 SPF 级雄性 SD 大鼠随机分为健康对照组、糖尿病模型 (DM) 和 DM + LRG 组。DM组和DM+LRG组分别给予生理盐水和LRG(0.6mg/kg/d)。12周后测量大鼠体重,采集内脏脂肪组织称重;然后使用 qRT-PCR 和蛋白质印迹法测量这些组织中血清生化指标和 FTO、AMPK 和 AKT 的水平。

结果

与对照组相比,DM组体重、内脏脂肪堆积和血糖、TG、TC和LDL-C水平显着升高,而HDL-C水平显着降低(p < 0.05)。LRG 治疗后,HDL-C 水平显着升高,但其他指标水平显着下降(p < 0.05)。与对照组相比,DM组内脏脂肪组织FTO和AKT水平显着升高,而AMPK水平显着降低(p < 0.05)。LRG治疗后,FTO和AKT水平显着降低,AMPK水平显着升高(p < 0.05)。

结论

LRG 可分别激活和抑制 AMPK 和 AKT 通路,降低 FTO 表达,从而减轻 2 型糖尿病患者的腹部肥胖。

更新日期:2021-09-14
down
wechat
bug